Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer. The TPST news feed on Stock Titan aggregates company announcements, financial updates, and regulatory milestones that shape the outlook for this oncology-focused biotech.
Investors following TPST news can expect frequent updates on the progress of Tempest’s key programs, including amezalpat (TPST-1120), a selective PPAR⍺ antagonist in development for hepatocellular carcinoma, and TPST-1495, a dual EP2/4 prostaglandin receptor antagonist being advanced for familial adenomatous polyposis. News items often highlight clinical data presentations, regulatory designations from agencies such as the FDA, EMA and China’s NMPA, and clearances or agreements for pivotal or registration-directed trials.
The company also regularly reports quarterly financial results and business updates, detailing research and development spending, cash position, and its ongoing evaluation of strategic alternatives. Capital markets activity, such as registered direct offerings of common stock, private placements of warrants, and shelf registration usage, is disclosed through press releases and corresponding SEC filings and is reflected in the TPST news stream.
In addition, Tempest issues news on strategic transactions, including its agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates, which is intended to expand and diversify its clinical-stage pipeline. For market participants tracking TPST, this news page provides a centralized view of clinical, regulatory, financial, and transactional developments. Users interested in Tempest’s evolving oncology pipeline and corporate strategy can review past announcements and monitor new releases as they are published.
Tempest Therapeutics (TPST) presented promising results from its TPST-1120 clinical program at the 2022 ASCO Annual Meeting. The drug demonstrated clinical benefits in patients with late-line advanced cancers, showing a 53% clinical benefit rate when used as monotherapy. In combination with anti-PD-1 therapy, it provided objective responses in patients previously resistant to such treatments. A potential biomarker for patient responsiveness was identified. Additionally, the company expects sufficient cash runway into the first quarter of 2024 to support ongoing studies.
Tempest Therapeutics (Nasdaq: TPST) announced its participation at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 a.m. ET. The company, focused on innovative oncology therapeutics, is advancing clinical programs TPST-1120 and TPST-1495 that target tumors through both targeted and immune-mediated mechanisms. TPST-1120 is undergoing a Phase 1b/2 study in collaboration with Roche for treating advanced hepatocellular carcinoma. For access to the presentation, visit Tempest's investor section online.
Tempest Therapeutics, Inc. (TPST) reported promising Phase 1 clinical trial results for its novel therapy, TPST-1120, both as a monotherapy and in combination with nivolumab. The data highlighted a 30% Objective Response Rate (ORR) at higher doses of TPST-1120 combined with nivolumab and a 53% Disease Control Rate (DCR) for patients on TPST-1120 alone. Notably, patients with advanced renal cell carcinoma showed a 50% ORR. The product displayed a favorable safety profile, with no severe toxicities reported. Continued development is expected, with results to be shared at the upcoming ASCO Annual Meeting.
Tempest Therapeutics, Inc. (TPST) recently announced the completion of enrollment in Phase 1 trials for TPST-1120, a PPARα antagonist, and presented promising preclinical data for TPST-1495 at the AACR Annual Meeting. The company reported a net loss of $8.5 million for Q1 2022, with cash reserves decreasing to $45.8 million, attributed to operational cash usage of $7.1 million. Amidst these financials, the company remains focused on upcoming clinical data presentations and has secured $15 million in PIPE financing to support ongoing development.
Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of two abstracts for presentation at the 2022 ASCO Annual Meeting. An oral presentation will detail Phase 1 trial results for TPST-1120, a PPARα antagonist, while a poster presentation will cover the ongoing TPST-1495 trial. CEO Stephen Brady emphasized the significance of these presentations, marking Tempest's first clinical data release. The abstracts will be available on ASCO's website on May 26, 2022. Key presentation details include dates and titles relevant to ongoing clinical investigations.
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced a $15 million PIPE financing, selling 3,149,912 shares at $2.36 each and pre-funded warrants at $2.359 to EcoR1 Capital and Versant Venture Capital. The financing aims to enhance the development of targeted cancer therapies. The transaction, expected to close by April 29, 2022, signifies trust from significant investors amidst current market conditions. The company plans to file a registration statement for the resale of shares involved in this placement.
Tempest Therapeutics (Nasdaq: TPST) presented promising preclinical data on April 8, 2022, regarding its innovative therapeutic programs at the AACR Annual Meeting. The data highlight the anti-tumor efficacy of TPST-1495, a dual antagonist targeting EP2 and EP4 receptors, showing superior tumor growth inhibition compared to single antagonists. Additionally, the TREX1 inhibitors demonstrated significant potential in activating the cGAS/STING pathway, crucial for immune response in tumors. These findings support ongoing clinical studies and underscore Tempest's commitment to developing first-in-class oncology treatments.
Tempest Therapeutics, Inc. (TPST) reported its financial results for 2021, highlighting significant achievements, including a successful merger and collaboration with Roche for TPST-1120. The company ended the year with $51.8 million in cash, a notable increase from $18.8 million in 2020. However, it recorded a net loss of $28.3 million, or $7.47 per share. R&D expenses rose to $17.2 million, indicating increased investment in drug development. Tempest anticipates presenting initial clinical data for TPST-1120 and TPST-1495 by early 2023, showcasing its robust cancer therapeutics pipeline.
Tempest Therapeutics (Nasdaq: TPST) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 10:40 a.m. ET. The company is focused on developing first-in-class therapeutics that integrate targeted and immune-mediated mechanisms for various tumors. Its clinical-stage programs, TPST-1120 and TPST-1495, are currently in Phase 1 trials. The company collaborates with F. Hoffmann La Roche for a global Phase 1b/2 study of TPST-1120 in advanced liver cancer patients. More details can be accessed at Tempest's investor site.
Tempest Therapeutics (Nasdaq: TPST) announced two poster presentations at the 2022 AACR virtual annual meeting scheduled for April 8-13, 2022. The presentations feature new preclinical data on TPST-1495, a clinical-stage dual EP2/4 antagonist, and TREX1, a preclinical STING agonist. Key presentations include: TPST-1495 focusing on the dual blockade of PGE2 receptors and TREX1 aimed at activating STING in metastatic disease. Both programs are designed to enhance tumor treatment via targeted and immune-mediated approaches.